| Name | Fondaparinux sodium |
| Description | Fondaparinux sodium (SR-90107A) is an antithrombin-dependent factor Xa inhibitor with antithrombotic activity. |
| In vitro | Fondaparinux sodium, the pioneering agent in a novel class of anticoagulants, selectively targets factor Xa with IC50 values (anti-Xa IU/ml) of 0.59±0.05 for activated monocytes (ac-M) and 0.17±0.03 for monocyte-derived microparticles (MMPs)[2]. |
| In vivo | Fondaparinux sodium exhibits a linear, dose-dependent pharmacokinetic profile ensuring a highly predictable response. It is fully bioavailable (100%), with a quick onset and a half-life of 14 to 16 hours, providing prolonged antithrombotic effects throughout a 24-hour period. Notably, the drug does not impact prothrombin time, activated partial thromboplastin time, or platelet function and aggregation[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 17.36 mM, Sonication is recommended.
DMSO : 60 mg/mL (34.72 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | Fxa | Fondaparinux sodium | Fondaparinux | Fondaparin | FactorXa | Factor Xa |
| Inhibitors Related | Edoxaban | Zifaxaban | Heparin sodium salt | Edoxaban Tosylate Monohydrate | Gabexate mesylate | Letaxaban | Apixaban | 2-Methoxyphenothiazine | 4-Chlorophenylurea | Fidexaban | Coumarin | Betrixaban |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Approved Drug Library | EMA Approved Drug Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Cardiovascular Disease Compound Library | FDA-Approved Drug Library | Metabolism Compound Library | Bioactive Compounds Library Max | Human Metabolite Library |
United States
